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Abstract
Background: When both parasite species are co-endemic, Plasmodium vivax incidence peaks in younger children compared
to P. falciparum. To identify differences in the number of blood stage infections of these species and its potential link to
acquisition of immunity, we have estimated the molecular force of blood-stage infection of P. vivax (molFOB, i.e. the number
of genetically distinct blood-stage infections over time), and compared it to previously reported values for P. falciparum.
Methods: P. vivax molFOB was estimated by high resolution genotyping parasites in samples collected over 16 months in a
cohort of 264 Papua New Guinean children living in an area highly endemic for P. falciparum and P. vivax. In this cohort, P.
vivax episodes decreased three-fold over the age range of 1–4.5 years.
Results: On average, children acquired 14.0 new P. vivax blood-stage clones/child/year-at-risk. While the incidence of clinical
P. vivax illness was strongly associated with molFOB (incidence rate ratio (IRR) = 1.99, 95% confidence interval (CI95) [1.80,
2.19]), molFOB did not change with age. The incidence of P. vivax showed a faster decrease with age in children with high
(IRR = 0.49, CI95 [0.38, 0.64] p,0.001) compared to those with low exposure (IRR = 0.63, CI95[0.43, 0.93] p = 0.02).
Conclusion: P. vivax molFOB is considerably higher than P. falciparum molFOB (5.5 clones/child/year-at-risk). The high number
of P. vivax clones that infect children in early childhood contribute to the rapid acquisition of immunity against clinical P.
vivax malaria.
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Introduction
Exposure to malaria – i.e. the number of blood-stage infections
acquired over time – determines to a large extent the frequency of
disease and can also explain seasonal patterns and age trends. The
number of infections acquired over time depends on transmission
intensity, with frequent bites by infected mosquitoes resulting in
high numbers of infections in a short period of time. In P. vivax,
additional blood-stage infections are caused by relapses from
dormant hypnozoites.
As people who live in malaria endemic areas achieve immunity
to disease after several years of exposure, newly acquired infections
do not always result in clinical episodes. The speed of acquisition
of immunity depends on transmission intensity [1–3] and also
differs between parasite species, with immunity to P. vivax
appearing to be acquired faster than immunity to P. falciparum
[4,5]. In numerous field studies conducted in areas co-endemic for
both species, the burden of P. vivax infections and disease was
found to peak at a younger age than that of P. falciparum [6–10].
The mechanisms underlying the immunity to malaria are not
entirely understood [2,11]. Whereas semi-immune people still
develop blood stage parasitemia, parasite densities are consider-
ably lower and rarely cause fever. Differences in the rate of natural
acquisition of immunity to P. falciparum and P. vivax may be the
result of differences in the immune responses induced by either
species, and/or a consequence of different numbers of infections
acquired over time.
Malaria infections consist of different parasite clones that can
infect individuals successively or simultaneously as multiple clone
infections. Clones differ in their polymorphic surface antigens as
well as in neutral genetic markers. Genotyping of such markers
allows discrimination of individual parasite clones during multiple
clone infections. The diversity of antigens is well documented in P.
falciparum [12–14] and P. vivax [15,16]. The large number of
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antigen variants is thought to allow parasites to escape the immune
system, as new infections likely express alleles different from
previous clones, and thus are not recognized by the present
humoral response [17,18]. Immunity is thus assumed to be largely
clone-specific, providing little cross-protection against heterolo-
gous clones [4,19–22].
Plasmodium falciparum clones transmitted by a mosquito bite
appear in the blood stream within 7–10 days. Albeit some of the
transmitted sporozoites might not establish blood-stage infections,
the number of genetically distinct clones detected in the blood-
stream over time (molFOB, as determined by genotyping) is a direct
measure of the molecular force of infection (molFOI, defined as
number of distinct clones entering the body over time). It is thus
closely linked to intensity of transmission [23].
In tropical and sub-tropical areas, P. vivax infectious mosquito
bites also lead to primary blood stage infections within 10–14 days.
In addition, a proportion of parasites remain dormant in the liver.
Relapses from such hypnozoites can then occur months later and
result in delayed blood stage infections. In high transmission
regions, such relapsing parasites are mostly genetically different
from parasites detected during the last acute blood stage infection
[24,25]. The relapsing clones might have been present earlier as
blood stage infection [26], or the primary and relapsing infections
are genetically different clones that were jointly transmitted in a
single mosquito bite with only one of these clones having emerged
from the liver. Thus, relapses may not only boost existing immune
responses by repeated exposure to the same parasite clone, but also
lead to a broader immune repertoire. No genotyping approach
allows differentiating a relapse from a primary blood stage
infection. The number of P. vivax parasites detected in the
peripheral blood in a given interval (molFOB) is therefore a
combination of primary blood-stage infections and relapses from
the same and/or earlier mosquito bites.
In order to assess the association between (individual) exposure
and risk of malaria, we followed 264 children aged 1 to 3 years at
enrolment in an area of high endemicity of P. falciparum and P.
vivax in Papua New Guinea (PNG) over 16 months [23,27,28]. As
in earlier studies in PNG [6,10,29], P. vivax incidence in this cohort
peaked in younger children compared to P. falciparum incidence
[27]. While P. vivax incidence decreased throughout the age group,
P. falciparum incidence increased between the ages of 1 to 3.5 years
with little change thereafter [27]. Previously we had estimated the
P. falciparum molFOI by msp2 genotyping, and shown that children
acquired 5.9 new P. falciparum infections per year-at-risk [23]. P.
falciparum molFOI increased significantly with age and was highly
predictive of incidence patterns [23].
The diversity and multiplicity of P. vivax in this cohort was
published previously [28]. In this paper, we present estimates of
the P. vivax molecular force of blood-stage infection (molFOB).
Methods
Ethics statement
Informed written consent was obtained from all parents or
guardians prior to recruitment of each child. Scientific approval
and ethical clearance for the study was obtained from the Medical
Research and Advisory Committee (MRAC 05.19 and 09.24) of
the Ministry of Health in PNG and from the Ethikkommission
beider Basel in Switzerland (no 03/06).
Field survey and patients
This study was conducted in Ilaita, a rural area near Maprik,
East Sepik Province, Papua New Guinea. A detailed description of
the study was given elsewhere [27]. Briefly, 264 study participants
were enrolled at an age of 10 to 38 months between March and
September 2006, and followed actively every 2 weeks to determine
malaria morbidity for a period of up to 16 months (until July
2007). In addition, children were actively checked every 8 to 9
weeks for the presence of malarial infections. Except for the first
and last round of active case detection, two consecutive blood
samples were collected by finger prick 24 hours apart from each
study participant at each follow-up visit. An individual thus
contributed up to 16 samples, 14 of which were paired samples
collected 24 hours apart. A passive case detection system was
maintained at the local health center and aid post throughout the
entire study period. At each episode of febrile illness, a blood
sample was collected from the participant and a rapid diagnostic
test (RDT) was performed and haemoglobin measured. Antima-
larial treatment with arthemeter-lumefantrine (AL) or in a few
cases with amodiaquine plus sulphadoxine-pyrimethamine was
administered upon a positive RDT or if haemoglobin levels were
less than 7.5 g/dl. In children with negative RDT, blood slides
were read within 24 hours, and microscopy positive children were
treated with AL.
Laboratory procedures
For genotyping individual P. vivax clones, the molecular markers
msp1F3 and MS16 were typed using capillary electrophoresis for
highly precise fragment sizing, which is a precondition for
longitudinal follow up of individual parasite clones. Both markers
proved to be highly polymorphic in the cohort with an expected
heterozygosity (He) of 97.8% for MS16 and 88.1% for msp1F3.
Details of the genotyping have been described previously [28].
Data analysis
In a previous analysis of the samples collected 24 hours apart,
we found that not all clones present in a host were detected within
a single sample. Twenty-one percent of all msp1F3 alleles and 28%
of all MS16 clones were missed on a single day [30]. Thus, we
used the combined genotyping data from both day 1 and day 2,
except for samples from enrolment and final visits, where only 1
venous blood sample was taken.
Author Summary
In areas where P. vivax and P. falciparum parasite species
co-occur, immunity to P. vivax seems to be acquired more
rapidly. This difference could be caused either by generic
differences in the way immunity is acquired or by a
relatively higher exposure to P. vivax blood-stage infec-
tions in early life. We found that children experienced an
average of 14 new P. vivax blood-stage infections per year,
and that the number of new infections acquired predicted
how often children fell ill with vivax malaria by genotyping
all P. vivax infections that occurred in a group of 264
children 1–4 years of age followed for 16 months. The
burden of blood-stage infections caused by P. vivax was
therefore at least twice as high as that caused by P.
falciparum. This higher force-of-blood-stage infection
(molFOB) caused by P. vivax is at least partially due to the
ability of P. vivax hypnozoites to relapse from long-lasting
liver stages. A high exposure to P. vivax blood-stage
infection resulted in more rapid decrease in the incidence
of P. vivax malaria. The high number of P. vivax clones that
infect children in early childhood is thus likely to
contribute substantially to the rapid acquisition of immu-
nity against clinical P. vivax malaria.
High Force of P. vivax Blood-Stage Infection
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The force of new P. vivax blood-stage infections (molFOB) was
generated by counting the number of genotypes in each interval
that had not been present in the preceding interval. An 8 to 9
weeks interval started on the first day after a regular cross-sectional
visit and included all samples collected during passive case
detection over two months plus the samples collected at the end
of the interval. molFOB was also determined for both markers
combined, msp1F3 and MS16. In case of discrepancy between the
markers for an 8-weeks interval the higher estimate from either
marker was used. This approach corrected for imperfect resolution
and detectability of a single marker.
Genotyping cannot directly identify relapses; molFOB measures
the combination of primary blood-stage infections and those caused
by relapsing hypnozoites. Thus, homologous relapses occurring in
two subsequent 2-month intervals would be misclassified as
persisting clones. New Guinean P. vivax strains are known to relapse
rapidly [31], however in regions of high transmission, relapsing
clones are usually of a different genotype than the initial blood stage
infection [24]. As a consequence the number of homologous
relapses that were not detected is expected to be relatively small.
In line with the pharmacokinetic properties of the drugs [32–
34], children were not considered at risk for two weeks after
treatment with artemether-lumefantrine and four weeks after
treatment with amodiaquine (AQ) plus sulphadoxine-pyrametha-
mine (SP). The force of blood-stage infection for each child and
interval was subsequently converted into the number of new clones
acquired per year-at-risk.
Similar to previous analyses of P. falciparum molFOI [23],
generalized linear mixed models (GLMMs) were used for analyses
of force of blood-stage infection as well as for incidence of P. vivax
episodes. These models were chosen because they allowed the
fixed effects to be specified separately from the random effects (i.e.
repeated measurements from the same child over time and
unmeasured village factors). Furthermore, the random-effects
model allowed for decomposition of the error into between-village
and within-village variation.
We fit a Poisson GLMMmodel with a log link to relate the fixed
and (Gaussian) random effects to the number of clinical episodes
experienced during a two month interval (defined as febrile illness
plus P. vivax .500 parasites/ml). Covariates were selected based on
earlier analyses of the same data [27]. Seasonality was character-
ized by two readily interpretable parameters: the amplitude, which
was half the range between the peak and trough, and the phase,
which was the location of the first zero crossing in a cycle relative
to the origin in time (in this case, the first week of the year). For
computational convenience, they were replaced by sine and cosine
terms with fixed phases. For all outcomes except prevalence, an
offset was fit to adjust for years at risk. Estimation of these models
was done using the LME4 package in R version 2.12 [35]. All
point estimates provided throughout the text (except those for
seasonal effects) were obtained from cubic splines fit using
generalized additive models (Figure 1) using the MGCV package
in R version 2.12 [36]. For a more detailed description of the
statistical approaches see [23]. Point estimates for seasonal peaks
and troughs were obtained from the GLMMs by setting all other
values of the covariates at their means. For the analyses of the
effect of exposure on the relationship between age and incidence of
P. vivax malaria, children were stratified into terciles according to
the average molFOB during the entire follow-up.
Results
A total of 264 children aged 0.9 to 3.2 years at baseline were
enrolled and followed up for 69 weeks. Out of 264 children, 248
(93.9%) were retained until the end of the study with 96.0%–
100.0% of children seen at each scheduled two-monthly survey.
Over the entire follow-up period, the age ranged from 0.9 to 4.5
years. A detailed description of this cohort was published
previously [27]. All but five children had at least one P. vivax
msp1F3 or MS16 PCR positive sample during the 16 months of
follow-up. Of all samples collected, 51.6% and 52.7% were
positive for msp1F3 and MS16, respectively, and 54.8% were
positive for either marker. In a total of 1448 P. vivax positive
samples, 2,305 and 3,372 distinct clones were detected by msp1F3
(65 different alleles) and MS16 (113 alleles) genotyping, respec-
tively.
Force of blood-stage infection
Excluding any period with residual drug levels from the time at
risk, each child was at risk of acquiring new infections for an
average of 0.93 years during the cohort (95% confidence interval
(CI95) [0.91, 0.96] range: 0.11–1.32). On average, 8.7 P. vivax
msp1F3 (CI95 [8.1, 9.4], range: 0–30) and 12.8 MS16 clones (CI95
[11.8, 13.7], range: 0–35) were found per child over the entire
follow-up period. When both markers were combined, an average
of 14.0 P. vivax clones were observed per child (CI95 [13.0, 15.0],
range 0–38).
The average molFOB was 9.4 new P. vivax infections per child
per year-at-risk by msp1F3 (CI95 [8.7, 10.0]), 13.8 by MS16 (CI95
[12.8, 14.8]) and 15.1 by both markers combined (CI95 [14.1,
16.2]). All further analyses were done for both markers combined.
In addition, children acquired an average of 5.1 different P.
falciparum msp2 clones during the cohort (CI95 [4.6, 5.6], range: 0–
19), resulting in a corresponding molFOB of 5.5 new P. falciparum
infections per child per year-at-risk (CI95 [5.0, 6.1]).
P. vivax molFOB showed a very pronounced seasonality (Figure 1,
Table 1, P,0.0001), peaking in early January (week 1, 17.1
clones/year-at-risk) and was lowest in early July (week 27, 11.3
clones/year-at-risk, Figure 2). molFOB was also significantly lower
in 2007 compared to 2006 (incidence rate ratio (IRR) 0.84, CI95
[0.77, 0.92], P=0.0002, Table 1, Figure 1). Regular ITN use was
associated with a significant reduction in acquisition of new clones
(IRR 0.66, CI95 [0.56, 0.77], P,0.0001, Table 1). Children with
antimalarial treatment in the preceding four weeks had a higher
molFOB than those that were not treated (IRR 1.24, CI95 [1.15,
1.33], P,0.0001, Table 1). molFOB did not vary significantly with
age (Figure 1, P (GLMM)= 0.6). There was significant variation in
molFOB between children in a village (P,0.001) but not between
villages (P=0.3, Table 1).
Predictors of clinical P. vivax illness
Over the 69 weeks of follow-up, a total of 1134 febrile episodes
with parasitemia of any parasite species and any parasite density
by light microscopy were observed, resulting in an incidence rate
(IR) of 4.60 episodes/year-at-risk [27]. P. vivax was the second
most common cause of malarial illness, causing 605 episodes
(IR=2.46) with any parasite density (supplementary Table 1). Of
these, 391 episodes (IR=1.59) fulfilled the more specific definition
of P. vivax malaria (i.e. febrile illness plus P. vivax parasitemia .500
parasites/ml) [37]. P. falciparum caused slightly more clinical
episodes (any density: 630 episodes (IR= 2.56); .2,500 para-
sites/ml: 472 episodes (IR= 1.92)).
As in earlier analyses [27], age and season were significant
predictors of clinical episodes of P. vivax malaria (Table 1). The
incidence of P. vivax malaria decreased log-linearly with age
(Figure 1, Table 1, P,0.0001) from 2.9 episodes/year-at-risk at 1
year of age to a minimum of 0.6 episodes at 3.5 years of age. It
peaked at the beginning of the rainy season (early December, week
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49, 1.7 clinical episodes, Figure 1) and was lowest in the early dry
season (early June, week 23, 0.8 clinical episodes, Figure 1).
Insecticide treated net (ITN) use was not significantly associated
with incidence of P. vivax malaria. The incidence of P. vivax malaria
varied significantly between villages (P,0.0001) and between
children living in the same village (P,0.0001).
When molFOB was added to the model (defined as the rate of
new clones acquired per year-at-risk), it was highly significantly
associated with the incidence of P. vivax malaria (Table 1,
P,0.0001). Adjusting for molFOB resulted in a 45% decrease in
seasonal differences in P. vivax incidence (Table 1, Figure 2).
Contrary to what was observed for P. falciparum [23], adding P.
vivax molFOB did not significantly alter the association of age or
ITN use with incidence of clinical P. vivax episodes. Comparable
results were seen when P. vivax episodes with any parasite density
were considered (Table S1).
In order to determine the association of exposure with the rate
of immune acquisition we stratified the cohort in children with
high (molFOB: 18.1–39.0/year-at-risk), medium (molFOB: 10.7–
18.0/year-at-risk) and low exposure (molFOB: 0–10.7/year-at-risk)
based on their average P. vivax molFOB. The reduction of incidence
of P. vivax episodes .500/ul with age was less pronounced in the
one third of children with the lowest average molFOB (IRR=0.63/
year increase in age, p= 0.02) than those with the highest exposure
(IRR=0.49/year increase in age, p,0.001) (Figure 3). Even
stronger differences were observed in associations of age with all P.
Figure 1. Age and seasonal patterns of molecular force of blood-stage infection (molFOB, Panel A) and incidence of clinical P. vivax
malaria (Panel B), and effects of ITN use on these parameters. Smooth splines from generalized additive models with single predictors and
95% confidence intervals.
doi:10.1371/journal.pntd.0002403.g001
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vivax episodes, where no significant reduction in incidence with
increasing age was found for children with low exposure
(IRR=0.93, p = 0.6), but strong reductions in children with
medium and high exposure (IRR=0.50–0.52, p,0.001, Figure 3).
These differences in IRR for P. vivax episodes of all densities with
age were statistically significant for children with low versus
medium (p= 0.03) and high exposure (p = 0.02), respectively. Due
to overall lower number of episodes with a parasitemia .500
parasites/ul (and thus reduced power), the differences between
children with low and medium exposure (p = 0.40) and low and
high exposure (p = 0.15) did not reach statistical significance.
Discussion
By genotyping all blood-stage parasites detected over 16 months
of follow-up, this study provides the first direct estimate of the
molecular force of P. vivax blood-stage infections. Children aged
0.9 to 4.5 years acquired 14.0 P. vivax clones per year-at-risk, thus
approximately twice as many as P. falciparum blood-stage clones
[23]. Differences between P. vivax and P. falciparum were not only
evident in the absolute number of infections, but also in the
associations between molFOB, incidence of clinical episodes and
age. While P. falciparum molFOB increased with age and thus
paralleled the trend in incidence [23], P. vivax molFOB did not
change with age, but incidence of disease decreased dramatically
over the age range of the cohort.
Minor differences in the typing techniques applied for these two
Plasmodium species could account for some differences in the
estimates. Typing was based on length polymorphic marker genes.
Their diversity was high, yet slightly differed: P. falciparum was
typed using msp2 (expected heterozygosity HE= 0.933) [38], while
msp1F3 (HE= 0.881) and MS16 (HE= 0.978) were used for P. vivax
typing [28]. For all three markers, we previously determined the
clone detectability, i.e. the proportion of clones detected in both of
two bleeds collected 24 hours apart. Detectability differed between
markers: 79% for Pfmsp2, 61% for PvMS16 and 73% for Pvmsp1F3
[30]. The overall diversity of the Pfmsp2 marker was therefore
intermediate to that of the two P. vivax markers, while Pfmsp2
detectability was highest.
The most obvious difference in typing strategies was that our
analysis of P. vivax was based on two loci with the combined
molFOB determined from maximal number of alleles per sample
observed by any marker. Thus, the ability to detect clones of both
P. vivax markers combined was higher than by the single P.
falciparum marker.
To assess the effect of the use of 2 markers, P. vivax molFOB was
also calculated using a single marker only. The average molFOB
was 8.7 and 12.8 clones/year-at-risk for msp1F3 and MS16,
respectively. Both of these values are substantially higher than the
5.5 clones/year-at-risk detected by Pfmsp2 genotyping. It is worth
noting that a 1.6 times higher molFOB was obtained with P. vivax
marker msp1F3 compared to P. falciparum despite its lower diversity
and detectability. Therefore, the differences in allelic diversity and
detectability of genotyping markers can not account for the large
differences between P. vivax and P. falciparum molFOB.
Given imperfect detectability and resolution of markers plus
infrequent sampling, our estimates of molFOB of both species were
likely underestimates of the true burden and complexity of
Table 1. Parameter estimates from GLMMs predicting the molecular force of P. vivax blood-stage infections (molFOB) and the
number of incident clinical episodes of P. vivax malaria with density .500 parasites/ml with and without adjustment for molFOB.
FOB P. vivax .500 episodes
P. vivax .500 episodes adjusted for
FOB
IRRa [CI95] p-value IRR
a [CI95] p-value IRR
a [CI95] p-value
Fixed effects
Age 0.55 [0.46–0.67] ,0.0001 0.52 [0.44–0.62] ,.0001
Sin(week) 0.99 [0.93–1.05] ,0.0001e 0.89 [0.77–1.03] ,0.0001e 0.94 [0.81–1.09] ,0.01e
Cos(week) 1.23 [1.18–1.29] ,0.0001e 1.45 [1.25–1.67] ,0.0001e 1.24 [1.07–1.44] ,0.01e
Average ITN useb 0.66 [0.56–0.77] ,0.0001
Treatedc 1.24 [1.16–1.33] ,0.0001
Year 2007 0.84 [0.77–0.92] 0.0002
FOB‘1/3 1.99 [1.8–2.19] ,0.0001
Random effects
Village 0.007 0.3 0.2 0.0001 0.35 ,0.0001
Child 0.2 ,0.0001 0.56 ,0.0001 0.28 ,0.0001
Log likelihood 2669 2551
AICd 1349 1115
Seasonal stats
Amplitude 0.21 0.39 0.22
Month of Peak early January early December early December
Month of Trough early July early June early June
aIRR: incidence rate ratio, CI95: 95% confidence interval.
binsecticide treated net use: 0% vs 100% use.
cTreated with antimalarials within 28days prior to start of interval.
dAkaike Information Criterium.
ejoint p-value for sine and cosine.
doi:10.1371/journal.pntd.0002403.t001
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Plasmodium spp. infection. However, for 97.5% (1638/1680) of all
regular follow-up bleeds (except baseline and the final round), two
paired samples taken 24 hours apart were available, thus the
probability of missing a clone in both of two paired samples
dropped to 0.07 for P. vivax msp1F3, 0.15 for P. vivax MS16 and
0.044 for P. falciparum msp2 [30] (assuming independence in the
chance to detect a clone from any one sample). In addition, clones
detected during passive case detection between regular visits were
also included, further reducing the chance of missing a clone
during an 8-week interval. This suggests that the estimates of
molFOB were biased downwards as a result of imperfect
detectability only by between 6 and 13% for P. vivax and 4% for
P. falciparum.
In PNG, P. vivax and P. falciparum are transmitted by the same
mosquito vectors. While no entomological studies were conducted
in parallel with this cohort, earlier studies in different PNG
lowland populations reported comparable sporozoite rates for P.
falciparum and P. vivax [6,39,40]. However, the likelihood that
individuals become infected with multiple P. vivax clones by a
single mosquito bite is high, because 75% of all P. vivax positive
individuals from our cohort carried multiple clone infections [28].
It is therefore likely that a mosquito takes up different P. vivax
gametocyte clones during a blood-meal, resulting in sexual
recombination and the transmission of a genetically diverse
inoculum to a new host. This contrasts to only 33% of multi-
clone infections in the P. falciparum positive children (Schoepflin,
Mueller & Felger unpublished results).
P. vivax parasites detected in the blood stream do not always
derive from a recent mosquito bite; they can also result from
relapsing hypnozoites. New Guinean P. vivax strains were reported
to relapse rapidly, and 63% of 1 to 5 year old children had a
recurrent parasitemia within six weeks after treatment of blood-
stage parasites [41]. Two thirds of those recurrent infections (all
post day 28) were of a different genotype [42]. Although
genotyping cannot differentiate between true new infections and
relapses of an unrelated genotype, P. vivax relapses likely contribute
significantly to the higher molFOB. Evidence for this comes from a
recent cohort of Papua New Guinean children aged 1 to 5 years,
in which the contribution of relapses to the burden of infection was
assessed directly by randomising one third of children to receive
anti-hypnozoite drug therapy with a 14 day course of high-dose
primaquine. While the primaquine treatment was not 100%
efficacious, it did nevertheless result in a 34–57% reduction in the
incidence of new P. vivax infections [43].
As a consequence of relapses, molFOB measures different
processes in P. vivax and P. falciparum. P. falciparum molFOB is
directly linked to transmission intensity in a given interval, whereas
molFOB of P. vivax represents a composite measure of both
Figure 3. Association of incidence of P. vivax episodes with age in children with low (molFOB: 0–10.7), medium (molFOB: 10.7–18.0)
and high average exposure (molFOB: 18.1–39.0) to P. vivax infections. Incidence rate ratio and 95% confidence intervals for changes
associated with 1 year increase in age.
doi:10.1371/journal.pntd.0002403.g003
Figure 2. Seasonality of P. vivax clinical episodes (as compared
to the first week of January, where incidence peaked)
excluding molFOB (blue) and adjusted for molFOB (red). molFOB
accounts for approximately 50% of the seasonal variation in incidence.
IRR = incidence rate ratio.
doi:10.1371/journal.pntd.0002403.g002
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transmission intensity and frequency and genetic complexity of
relapsing parasites (some of which may have been acquired
months or years earlier). P. vivax molFOB is therefore not a direct
measure of molFOI (i.e. the number of new parasites acquired by
the human host), but the difference between the two measures is
small if the total follow-up period is substantially longer than the
average relapse frequency. In the Southwest Pacific, P. vivax
infections are thought to relapse very rapidly (i.e. within a few
weeks [31]), thus P. vivax molFOB is a good surrogate marker for
molFOI if calculated over the entire 16 months of follow-up.
Interestingly, P. vivax molFOB did not change with age, while P.
falciparum molFOI was strongly age dependent and increased from 3
to 8 clones per year-at-risk over the age range of 1–4.5 years of this
cohort [28]. As a consequence, molFOI largely explained the age
trend in P. falciparum incidence (increasing from 1 episode per year
in children one year of age to 2.5 in children three years of age)
[23]. In contrast, P. vivax molFOB did not explain the decrease in P.
vivax incidence from over 3 episodes per year in children one year
of age to less than 1 episode in children older than three years.
The age shift in incidence in clinical disease caused by P. vivax
and P. falciparum observed in this study – i.e. P. vivax incidence
peaking in younger children - parallels earlier findings in Papua
New Guinea [6,10,29] and other regions where both species are
co-endemic [7–9]. This indicates a rapid acquisition of immunity
to P. vivax in individuals with life-long exposure to both P.
falciparum and P. vivax. As immunity to malaria builds up gradually
and is thought to be strain-specific [4,5], it is likely that the
number of distinct infections acquired over an individual’s lifetime
is a major driving force for acquisition of immunity [20].
In their first years of life, the children in our cohort were
estimated to have acquired three times more genetically distinct P.
vivax than P. falciparum infections. In both species a higher molFOB
was itself associated with a significant increase in incidence of
clinical disease. However, a more rapid decrease in incidence of P.
vivax malaria was observed in children exposed to high compared
to low levels of P. vivax infections (Figure 3). Although notable
against P. vivax episodes with .500 parasites/ml, this effect of
exposure on age-specific risk of P. vivax malaria was more
pronounced when all P. vivax episodes (irrespective of parasitae-
mia) were considered. While the incidence of P. vivax malaria
.500 parasites/ml decreased, even in children with low exposure,
the incidence of P. vivax of any density did not change significantly
with age in the children with the low exposure. This indicates that,
in children with low exposure, those .3 years acquired some
immunity against high-density clinical P. vivax episodes, but not
against those associated with low levels of parasitaemia. Together
these observations suggest that high molFOB, and consequently the
overall genetic diversity to which children were exposed in early
childhood, contribute substantially to the rapid acquisition of
clinical immunity to P. vivax across the entire age range [27].
The high exposure to P. vivax may even be sufficient for children
to acquire a certain degree of immunity against P. vivax infection.
With at least some malaria vectors, biting rates increase with host
body size [44]. Therefore, as children grow older, their exposure
to malarial infection also increases, as supported by the strong age-
dependence of P. falciparum molFOI [28]. The lack of an association
of P. vivax molFOB with age suggests that, in older children, some of
the P. vivax sporozoites transmitted by mosquitoes do not succeed
in establishing detectable blood stage infections.
Conclusions
We propose that the high number of genetically distinct P. vivax
blood stages infections acquired in the first 4 years of life (as
measured by molFOB) is a significant contributor to the rapid
acquisition of immunity against clinical P. vivax malaria. Albeit less
closely linked to transmission (i.e. force of infection (FOI)) than in
P. falciparum [23], molFOB is nevertheless a measure of individual
exposure to P. vivax blood-stage infection and is significantly linked
to the observed burden of P. vivax malaria. As such, it could be
used as both a surrogate maker for exposure and as a parameter
for monitoring the impact of antimalarial interventions.
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